Investing.com - Kymera Therapeutics Inc , (NASDAQ:KYMR) a clinical-stage biopharmaceutical firm specializing in the development of novel small molecule medicines using targeted protein degradation (TPD), surged 23.7% on Tuesday following a significant announcement.
After an Independent Data Review Committee examined the preliminary safety and efficacy data of KT-474, pharmaceutical giant Sanofi (EPA:SASY) has indicated its intention to expand the ongoing Phase 2 trials for Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD). This move is expected to expedite the progression towards pivotal studies.
Nello Mainolfi, PhD, Founder, President, and CEO of Kymera Therapeutics, expressed enthusiasm, noting, “This expansion, supported by the results of the interim analysis, is intended to accelerate overall timelines and inform future registrational trials. We look forward to sharing further information as it is available, including trial designs and updated timing for the expanded Phase 2 data readouts.”
Analysts from Truist and Stifel also responded positively to the news. Truist analysts stated that the Phase 2 HS/AD expansion of KT-474 after the interim analysis bodes well for the program, reiterating a 'Buy' stance.
Meanwhile, Stifel analysts suggested that the update strongly indicates that KT-474 has demonstrated an efficacy signal with clean early safety in more than one disease. This should enhance the value for this asset and Kymera's co-co opt-in.